Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGPAT2 | O15120 | 13/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4279053 | 0.89 | RECQL (0.60) | AGPAT2RECQLALDH1A1MEN1LMNA | |
| SCHEMBL9566471 | 0.83 | RECQL (0.78) | AGPAT2RECQLALDH1A1MEN1LMNA | |
| SCHEMBL4277512 | 0.77 | AGPAT2 (1.00) | AGPAT2RECQLALDH1A1MEN1KMT2A | |
| SCHEMBL4282014 | 0.76 | RECQL (0.57) | AGPAT2RECQLALDH1A1MEN1LMNA | |
| SCHEMBL4281980 | 0.76 | AGPAT2 (0.67) | AGPAT2RECQLALDH1A1KDM4E | |
| SCHEMBL4280537 | 0.76 | HSP90AA1 (0.71) | AGPAT2RECQLALDH1A1KDM4E | |
| SCHEMBL5375905 | 0.76 | AGPAT2 (0.67) | AGPAT2RECQLALDH1A1MEN1LMNA | |
| SCHEMBL5305206 | 0.75 | PTGS2 (0.53) | AGPAT2ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL7699644 | 0.74 | ALDH1A1 (0.56) | AGPAT2RECQLALDH1A1MEN1LMNA | |
| SCHEMBL5386005 | 0.73 | ALDH1A1 (0.57) | AGPAT2RECQLALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099183-A1 | PYRIMIDINES AND USES THEREOF | CELL THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-7419984-B2 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20040204386-A1 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204386-A1 | Pyrimidines and uses thereof | LPCAT3, LPCAT1, APRT | AGPAT2 100/4885RECQL 1820/4885ALDH1A1 1326/4885 |
| US-20090099183-A1 | PYRIMIDINES AND USES THEREOF | LPCAT3, LPCAT1, APRT | AGPAT2 94/4885RECQL 2213/4885ALDH1A1 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.